Bnp Paribas Asset Management Holding S.A. Viridian Therapeutics, Inc.\De Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 680 shares of VRDN stock, worth $16,360. This represents 0.0% of its overall portfolio holdings.
Number of Shares
680Holding current value
$16,360% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
185Shares Held
83.1MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$129 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$117 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$115 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$108 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$107 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $960M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...